To elucidate the role of thrombocytosis, alone or in combination with standard (age, previous cardiovascular events) and novel (leukocytosis, JAK2(V617F) mutational status) risk factors, in the cardiovascular events of essential thrombocythemia (ET), we analyzed a cohort of 1063 patients. We found that a platelet count at diagnosis greater than 1000 x 10(9)/L was associated with significantly lower rate of thrombosis in multivariable analysis and, if combined with leukocytes less than 11 x 10(9)/L, pointed to a "low-risk" category with a rate of thrombosis of 1.59% of patients/year. On the contrary, the highest risk category (thrombosis rate, 2.95% of patients/year) was constituted of patients with leukocytosis, lower platelet count, and a JAK2(V617F) mutated genotype in most cases (77% vs 26% in the low-risk group), independently from standard risk factors. These data challenge the theory that elevated platelet count increases thrombosis risk in ET and suggest prospective clinical trials to support this hypothesis
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia / A. Carobbio; G. Finazzi; E. Antonioli; P. Guglielmelli; A.M. Vannucchi; F. Delaini; V. Guerini; M. Ruggeri; F. Rodeghiero; A. Rambaldi; T. Barbui. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 112(8):(2008), pp. 3135-3137. [10.1182/blood-2008-04-153783]
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia
ANTONIOLI, ELISABETTA;GUGLIELMELLI, PAOLA;VANNUCCHI, ALESSANDRO MARIA;
2008
Abstract
To elucidate the role of thrombocytosis, alone or in combination with standard (age, previous cardiovascular events) and novel (leukocytosis, JAK2(V617F) mutational status) risk factors, in the cardiovascular events of essential thrombocythemia (ET), we analyzed a cohort of 1063 patients. We found that a platelet count at diagnosis greater than 1000 x 10(9)/L was associated with significantly lower rate of thrombosis in multivariable analysis and, if combined with leukocytes less than 11 x 10(9)/L, pointed to a "low-risk" category with a rate of thrombosis of 1.59% of patients/year. On the contrary, the highest risk category (thrombosis rate, 2.95% of patients/year) was constituted of patients with leukocytosis, lower platelet count, and a JAK2(V617F) mutated genotype in most cases (77% vs 26% in the low-risk group), independently from standard risk factors. These data challenge the theory that elevated platelet count increases thrombosis risk in ET and suggest prospective clinical trials to support this hypothesisFile | Dimensione | Formato | |
---|---|---|---|
Carobbio, Blood_2008.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
168.32 kB
Formato
Adobe PDF
|
168.32 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.